Six trials (4,190 participants) were included. One trial had 3,006 participants and others ranged from 80 to 619 participants. Overall 2,846 were randomised to paclitaxel-eluting stents.
Tests showed no evidence of publication bias.
Compared to bare-metal stents, paclitaxel-eluting stents had no effect on mortality, recurrent myocardial infarction and stent thrombosis with no evidence of heterogeneity.
Paclitaxel-eluting stents were associated with a reduced risk of revascularisation (OR 0.56, 95% CI 0.44 to 0.72, I2=5.5%).